4-[(1E)-2-(phenyl)ethenyl]benzenemethanamine | 36092-33-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[(1E)-2-(phenyl)ethenyl]benzenemethanamine
• 英文别名: trans-4-Aminomethyl-stilben；4-trans-styryl-benzylamine；(E)-(4-Styrylphenyl)methanamine；[4-[(E)-2-phenylethenyl]phenyl]methanamine
• CAS: 36092-33-8
• 化学式: C₁₅H₁₅N
• 分子量: 209.291
• InChiKey: CTTPWMUJYDYVHC-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-[(1E)-2-(phenyl)ethenyl]benzenemethanamine 生成 (E)-N-(4-styrylbenzyl)benzamide
  参考文献：
  名称：

  56. 4-苯乙烯基苄胺和4-苯乙烯基苄基二甲基胺

  摘要：

  DOI：

  10.1039/jr9480000224
• 作为产物：
  描述：

  反式二苯乙烯-4-甲醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 肼 作用下， 以 乙醇 为溶剂， 生成 4-[(1E)-2-(phenyl)ethenyl]benzenemethanamine
  参考文献：
  名称：

  Synthesis, Dual Fluorescence, and Fluoroionophoric Behavior of Dipyridylaminomethylstilbenes

  摘要：

  The synthesis, dual fluorescence, and fluoroionophoric behavior of two donor-sigma spacer-acceptor (D-s-A) compounds, trans-4-(N,N-bis(2-pyridyl)amino)methylstilbene (111) and trans-4-(N,N-bis(2pyridyl)amino)methyl-4'-cyanostilbene (1CN), are reported and compared to that of trans-4-(N,N-bis(2-pyridyl)amino)methyl-4'-(N V-dimethylamino)stilbene (1DPA). To gain insights into the dual fluorescence properties for 1H and 1CN in polar but not in nonpolar solvents, model compounds resulting from a replacement of the stilbene group by alkyl (2R) or xylyl (2X) groups or from a replacement of the dipyridylamino (dpa) group by dianisoleamino (MA), diethylamino (ME), methylanilino (MP), or diphenylamino (3PP) groups also have been investigated. In addition to 1H and 1CN, all four compounds of 3 display dual fluorescence. The locally excited (LE) fluorescence mainly results from the stilbene group and the ICT fluorescence from the through-bond interactions between the amino donor and the stilbene acceptors. In the presence of transition metal ions such as Zn(II), Ni(II), Cu(II), and Cd(II), the ICT processes are switched from dpa (D) -> stilbene (A) in 1H and 1CN to stilbene (D) -> dpa/metal ion (A) in their complexes. Whereas the ICT states for the complexes are generally nonfluorescent, an exception was found for the case of 1H/Zn(II). As a result, substituent-dependent fluoroionophoric behavior has been demonstrated by III, 1CN, and 1DPA in response to Zn(II).

  DOI：

  10.1021/jo0509049

文献信息

• Ambient-Temperature Synthesis of Primary Amines via Reductive Amination of Carbonyl Compounds
  作者：Chao Xie、Jinliang Song、Manli Hua、Yue Hu、Xin Huang、Haoran Wu、Guanying Yang、Buxing Han

  DOI：10.1021/acscatal.0c01872

  日期：2020.7.17

  Efficient synthesis of primary amines via low-temperature reductive amination of carbonyl compounds using NH3 and H2 as the nitrogen and hydrogen resources is highly desired and challenging in the chemistry community. Herein, we employed naturally occurring phytic acid as a renewable precursor to fabricate titanium phosphate (TiP)-supported Ru nanocatalysts with different reduction degrees of RuO2

  在化学界中，非常需要通过使用NH 3和H 2作为氮和氢资源通过羰基化合物的低温还原胺化来高效合成伯胺。在本文中，我们采用天然植酸作为可再生前体，以制备具有不同还原度的RuO 2（Ru / TiP- x，x代表还原温度），将球磨和熔融盐法相结合。非常有趣的是，所得的Ru / TiP-100在室温下对羰基化合物的还原胺化反应具有良好的催化性能，这是由于载体（TiP）和Ru / RuO 2与适当比例的Ru 0协同作用所致。（52％）。各种羰基化合物可以高产率有效地转化为相应的伯胺。更重要的是，还可以在环境温度下实现具有可还原基团的其他底物的转化。详细的研究表明，部分还原的Ru和支持物（TiP）是必不可少的。Ru / TiP-100催化剂的高活性和选择性源于较高的酸度和金属Ru 0的合适电子密度。
• Synthesis and Characterization of Fluorescent Ligands for the Norepinephrine Transporter:  Potential Neuroblastoma Imaging Agents
  作者：Dirk Hadrich、Frank Berthold、Eberhard Steckhan、Heinz Bönisch

  DOI：10.1021/jm9811155

  日期：1999.8.1

  3S)-2beta-ethoxycarbonyl-3beta-tropanyl 5-(dimethylamino)naphthalene-1-sulfonate (6), exhibited high affinity (IC(50) about 50 nM) for the NET. The nisoxetine derivatives 8 (rac-N-[(3-methylamino-1-phenyl)propyl]-5-(dimethylamino)-1-naphthale nesulfonamide) and 9 (rac-4-[(3-methylamino-1-phenyl)propyl]amino-7-nitro-2,1, 3-benzoxadiazole) and especially the guanidine derivative 4 (1-[4-(4-phenyl-1,3-butadieny

  放射性标记的间碘苄基胍（MIBG）是一种寻找肿瘤的放射性药物，用于诊断和治疗嗜铬细胞瘤和神经母细胞瘤。它通过几乎在所有成神经细胞瘤细胞中表达的神经元去甲肾上腺素（NE）转运蛋白（NET）转运到肿瘤细胞中。在这里，我们描述了一系列与NET底物MIBG或NET抑制剂（-）-（2R，3S）-可卡因和尼西西汀相关的荧光化合物的合成及其某些药理性质。10种合成荧光化合物中的3种，分别是1-（1-萘甲基）胍基硫酸盐（1），1- [2-（dibenz [b，f] azepin-5-yl）乙基]胍基硫酸盐（2）和（2R， 3S）-2β-乙氧基羰基-3β-戊基5-（二甲氨基）萘-1-磺酸盐（6）对NET表现出高亲和力（IC（50）约为50 nM）。尼索西汀衍生物8（rac-N-[（3-甲基氨基-1-苯基）丙基] -5-（二甲基氨基）-1-萘磺酰胺）和9（rac-4-[（3-甲基氨基-1-苯基）丙基]氨基-7-硝基-2
• A Unique Synthetic Method for Pyridine-Ring Containing Ter-, Quater- and Quinquearyl and Vinylogues by Thermolysis of 2,2-Dichlorocyclopropylmethyleneamines
  作者：Shinzo Kagabu、Shinji Mizoguchi

  DOI：10.1055/s-1996-4220

  日期：1996.3

  Teraryls, quateraryls, and quinquearyls composed of a pyridine ring in the segment and their vinylogues were prepared directly by thermal rearrangement of N-(hetero)arylmethyl-2,2-dichloro-1-substituted phenylcyclopropylmethyleneamines in modest to good yields.

  通过对 N-（杂）芳基甲基-2,2-二氯-1-取代苯基环丙基亚甲基胺进行热重排，直接制备了在段中由一个吡啶环组成的三元、四元和五元及其乙烯基对映体，收率从一般到良好。
• METALLOPROTEIN INHIBITORS
  申请人：Puerta T. David

  公开号：US20070117848A1

  公开（公告）日：2007-05-24

  The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R 1 , R 2 , R 3 , and R 4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

  本发明涉及金属蛋白酶抑制剂，包括：a. 有机取代基和至少一个锌结合基团（ZBG）共价连接在一起；或者b. 通过侧链取代的ZBG，其中ZBG的公式为（I）：其中X为O或S，每个R1、R2、R3和R4分别为氢或有机基团。这些金属蛋白酶抑制剂可用于预防或治疗与病理性金属蛋白酶活性相关的病理性疾病、状况或症状，或者通过抑制该活性缓解的病理性疾病、状况或症状。
• 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I
  申请人：METZ, JR. William Arthur

  公开号：US20090082340A1

  公开（公告）日：2009-03-26

  The present invention discloses and claims methods for the treatment of a patient suffering from a disease or disorder ameliorated by inhibition of casein kinase Iε activity comprising the administration of a compounds of formula (I) and formula (II) as inhibitors of human casein kinase Iε, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II) useful in the claimed methods of treatment are also disclosed.

  本发明揭示和声明了治疗因抑制酪蛋白激酶Iε活性而改善的疾病或疾病患者的方法，包括给予公式（I）和公式（II）化合物作为人类酪蛋白激酶Iε的抑制剂，并使用公式（I）和公式（II）化合物治疗中枢神经系统疾病和疾病，包括情绪障碍和睡眠障碍的方法。本文中定义了R基取代基，还揭示了包含公式（I）或公式（II）化合物的制药组合物，可用于所声明的治疗方法。